Want to see STIM full AI Analyst Report?
STIM Stock Chart & Stats
$3.00
$0.08(4.62%)
At close: 4:00 PM EDT
$3.00
$0.08(4.62%)
Day’s Range― - ―
52-Week Range$0.80 - $3.44
Previous Close$1.8
Volume807.96K
Average Volume (3M)2.48M
Market Cap
$210.30M
Enterprise Value$160.20
Total Cash (Recent Filing)$19.43M
Total Debt (Recent Filing)$86.52M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Nov 10, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding76,197,220
10 Day Avg. Volume1,594,451
30 Day Avg. Volume2,479,624
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.07
Price to Sales (P/S)0.61
P/FCF Ratio-4.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside66.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$161.77M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthThe sharp increase in trailing revenue shows meaningful expansion in the company’s commercial base and demand for its offerings. If sustained, this growth can improve operating leverage, support reinvestment, and strengthen Neuronetics’ position in the expanding interventional mental-health market over the next several quarters.
Improving Margins And Cost DisciplineMargin expansion alongside lower operating expenses indicates progress toward a more efficient operating model, supported by mix, pricing, revenue-cycle improvements, and cost controls. This combination improves the path toward sustainable profitability and gives management greater flexibility to fund growth without proportionate spending increases.
Greenbrook Growth And Operating ImprovementGreenbrook’s growth and improved collections demonstrate that the clinic platform can contribute both increasing revenue and better economics. Stronger payer contracting and revenue-cycle execution may create durable operating benefits by improving cash conversion, clinic productivity, and the scalability of Neuronetics’ broader neurohealth model.
Bears Say
Persistent Losses And Negative Cash FlowNeuronetics remains dependent on improved execution before it can internally fund operations, because both operating and free cash flow are still negative and profitability has not been achieved. Continued cash burn can constrain investment, increase financing needs, and make the transition to a durable earnings model more difficult.
High Financial LeverageVery high leverage reduces financial flexibility while the company is still loss-making and cash-flow negative. A heavily debt-funded balance sheet can increase refinancing and interest burdens, limit the ability to absorb operating setbacks, and leave less capacity for strategic investment until business performance improves materially.
NeuroStar Transition And Underused CapacityThe core NeuroStar business is facing execution complexity as customers shift among purchase, lease, and session models, while substantial clinic capacity remains unused. These factors can create uneven revenue recognition, delay utilization-driven operating leverage, and make the timing of sustained growth and profitability less predictable.
Neuronetics News
STIM FAQ
What was Neuronetics Inc’s price range in the past 12 months?
Neuronetics Inc lowest stock price was $0.80 and its highest was $3.44 in the past 12 months.
What is Neuronetics Inc’s market cap?
Neuronetics Inc’s market cap is $210.30M.
When is Neuronetics Inc’s upcoming earnings report date?
Neuronetics Inc’s upcoming earnings report date is Nov 10, 2026 which is in 53 days.
How were Neuronetics Inc’s earnings last quarter?
Neuronetics Inc released its earnings results on Aug 11, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.123 by $0.073.
Is Neuronetics Inc overvalued?
According to Wall Street analysts Neuronetics Inc’s price is currently Undervalued.
Does Neuronetics Inc pay dividends?
Neuronetics Inc does not currently pay dividends.
What is Neuronetics Inc’s EPS estimate?
Neuronetics Inc’s EPS estimate is -0.09.
How many shares outstanding does Neuronetics Inc have?
Neuronetics Inc has 76,197,220 shares outstanding.
What happened to Neuronetics Inc’s price movement after its last earnings report?
Neuronetics Inc reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.123. Following the earnings report the stock price went up 47.005%.
Which hedge fund is a major shareholder of Neuronetics Inc?
Currently, no hedge funds are holding shares in STIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuronetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (66.67% Upside)
$5.00 (66.67% Upside)
Blogger Sentiment
Bullish
STIM Sentiment 67%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $44.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Neuronetics Inc
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
STIM Company Deck
STIM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed measurable operational and financial progress: revenue growth (9.1%), strong Greenbrook performance (+16.8%), margin expansion (to 51.1%), reduced OPEX (-12%), an improved net loss and a positive adjusted EBITDA, plus strengthened cash and an ATM raise. These positives were balanced against execution and timing risks centered on NeuroStar's transition (NeuroStar revenue down 2.7% and sessions down double digits due to inventory normalization and mix shifts), underused clinic capacity (~40%), potential short-term revenue choppiness as customers migrate to new purchase/lease models, and dependence on external regulatory timelines for psychedelics. On balance, the company demonstrated tangible progress toward profitability and cash generation while acknowledging near-term mix and execution challenges.View all STIM earnings summariesSTIM Stock 12 Month Forecast
Average Price Target
$5.00
▲(66.67% Upside)
Technical Analysis
Ownership Overview
28.52% Insiders
5.09% Mutual Funds
36.11% Other Institutional Investors
26.72% Public Companies and
Individual Investors